earnings
Historic Profitability Secured: argenx Posts First Operating Profit (ARGX Q4 2025 Earnings Call)
argenx delivered its first full year of operating profitability in fiscal year 2025, driven by surging global adoption of its core immunology biologic VYVGART. The company capped the year with record net sales and a pivotal Phase III clinical trial victory in ocular myasthenia gravis, solidifying its leadership in FcRn-targeted therapeutics.